argenx SE (NASDAQ:ARGX) Shares Sold by Franklin Resources Inc.

Franklin Resources Inc. cut its stake in argenx SE (NASDAQ:ARGX) by 1.6% during the 3rd quarter, Holdings Channel.com reports. The fund owned 134,018 shares of the company’s stock after selling 2,204 shares during the period. Franklin Resources Inc.’s holdings in argenx were worth $72,847,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of ARGX. Wilmington Savings Fund Society FSB purchased a new stake in shares of argenx during the 3rd quarter valued at $652,000. Sanctuary Advisors LLC grew its position in argenx by 17.5% during the third quarter. Sanctuary Advisors LLC now owns 2,064 shares of the company’s stock valued at $1,119,000 after acquiring an additional 308 shares during the period. M&T Bank Corp increased its stake in argenx by 7.2% during the third quarter. M&T Bank Corp now owns 4,307 shares of the company’s stock worth $2,335,000 after acquiring an additional 289 shares during the last quarter. MML Investors Services LLC increased its position in argenx by 16.9% during the 3rd quarter. MML Investors Services LLC now owns 8,699 shares of the company’s stock worth $4,715,000 after purchasing an additional 1,255 shares in the last quarter. Finally, Orion Portfolio Solutions LLC raised its holdings in argenx by 2.7% in the third quarter. Orion Portfolio Solutions LLC now owns 8,800 shares of the company’s stock valued at $4,768,000 after buying an additional 234 shares during the period. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Stock Up 4.2 %

ARGX opened at $632.64 on Tuesday. The company’s 50-day moving average price is $583.23 and its 200 day moving average price is $517.38. argenx SE has a fifty-two week low of $327.73 and a fifty-two week high of $643.63. The firm has a market cap of $38.19 billion, a price-to-earnings ratio of -718.91 and a beta of 0.59.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. The firm had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same period in the prior year, the business earned ($1.25) EPS. Research analysts anticipate that argenx SE will post 2.2 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on ARGX shares. Deutsche Bank Aktiengesellschaft lowered shares of argenx from a “buy” rating to a “hold” rating in a research report on Friday, October 4th. Citigroup boosted their price objective on argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Raymond James reiterated a “strong-buy” rating and set a $605.00 target price on shares of argenx in a report on Thursday, October 10th. Wedbush restated an “outperform” rating and issued a $655.00 price target on shares of argenx in a report on Tuesday, December 3rd. Finally, Truist Financial lifted their price target on shares of argenx from $540.00 to $660.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $635.11.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.